Breaking the Limitation of a Blood Draw to Design a Better Patient Treatment Plan in Cardiology and Oncology
HaimaChek™ has developed a revolutionary minimally invasive platform technology which is capable of capturing and isolating specific rare cells out of the bloodstream. These cells can be used to design a personalized treatment plan in cardiology and oncology.
Our in vivo methodology screens 100 times more blood than current standard liquid biopsies, enabling much earlier disease detection and much more precise analysis of the screened disease.
Our fields of activity
Cardiology
Heart infarction, covid-19, diabetes, and heart failure all cause the level of circulating endothelial cells to increase in the bloodstream. This biomarker has the potential to personalize the treatment of millions of patients.
Oncology
Current technologies are not sufficient to detect early primary tumors or metastases. This inhibits a physician’s ability to determine the optimal treatment course in many situations.
Who we are
HaimaChek™ was founded in 2016 to develop a novel medical device to personalize treatment in cardiology and oncology. Today, our management team consists of entrepreneurs, physicians, and legal experts. Get to know them!
Our collaborative Partners
We have teamed up with clinical partners in the field of lung and prostate cancer for our next step: the in vivo clinical study.
Contact
If you have any questions or need further information,
please feel free to contact us.